MicroRNA-126 Inhibits SOX2 Expression and Contributes to Gastric Carcinogenesis

Takeshi Otsubo, Yoshimitsu Akiyama, Yutaka Hashimoto, Shu Shimada, Kentaro Goto, Yasuhito Yuasa

Department of Molecular Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

Abstract

Background: SRY (sex-determining region Y)-box 2 (SOX2) is a crucial transcription factor for the maintenance of embryonic stem cell pluripotency and the determination of cell fate. Previously, we demonstrated that SOX2 plays important roles in growth inhibition through cell cycle arrest and apoptosis, and that SOX2 expression is frequently down-regulated in gastric cancers. However, the mechanisms underlying loss of SOX2 expression and its target genes involved in gastric carcinogenesis remain largely unknown. Here, we assessed whether microRNAs (miRNAs) regulate SOX2 expression in gastric cancers. Furthermore, we attempted to find downstream target genes of SOX2 contributing to gastric carcinogenesis.

Methodology/Principal Findings: We performed in silico analysis and focused on miRNA-126 (miR-126) as a potential SOX2 regulator. Gain- and loss-of-function experiments and luciferase assays revealed that miR-126 inhibited SOX2 expression by targeting two binding sites in the 3'-untranslated region (3'-UTR) of SOX2 mRNA in multiple cell lines. In addition, miR-126 was highly expressed in some cultured and primary gastric cancer cells with low SOX2 protein levels. Furthermore, exogenous miR-126 over-expression as well as siRNA-mediated knockdown of SOX2 significantly enhanced the anchorage-dependent and -independent growth of gastric cancer cell lines. We next performed microarray analysis after SOX2 over-expression in a gastric cancer cell line, and found that the expression of the placenta-specific 1 (PLAC1) gene was significantly down-regulated by SOX2 over-expression. siRNA- and miR-126-mediated SOX2 knockdown experiments revealed that miR-126 positively regulated PLAC1 expression through suppression of SOX2 expression in gastric cancer cells.

Conclusions: Taken together, our results indicate that miR-126 is a novel miRNA that targets SOX2, and PLAC1 may be a novel downstream target gene of SOX2 in gastric cancer cells. These findings suggest that aberrant over-expression of miR-126 and consequent SOX2 down-regulation may contribute to gastric carcinogenesis.

Introduction

The SOX2 gene encodes a member of the SRY-related HMG-box (SOX) family of transcription factors involved in the regulation of embryonic development and in the determination of cell fate [1,2,3]. In particular, it is well known that SOX2 plays important roles in maintenance of embryonic stem (ES) cell self-renewal and pluripotency [4,5]. Among adult tissues, SOX2 is expressed in the brain, retina, tongue, lung, esophagus and stomach, and plays crucial roles in the differentiation and morphogenesis of these organs [6,7,8]. We previously reported that SOX2 mRNA and protein were expressed in normal gastric mucosa, but frequently down-regulated in human gastric cancer tissues and cell lines, some of which are due to aberrant DNA methylation [9,10]. We further revealed that SOX2 plays important roles in growth inhibition through cell cycle arrest and apoptosis, indicating that SOX2 may have tumor-suppressive functions in gastric cancer cells [10]. However, the downstream target genes of SOX2 involved in gastric carcinogenesis remain largely unknown.

MicroRNAs (miRNAs) are small, approximately 22-nucleotide, noncoding RNAs that regulate the expression of hundreds of genes by targeting their mRNAs posttranscriptionally [11]. miRNAs bind to the partially complementary target sites in 3'-untranslated regions (3'-UTRs) of mRNAs, inducing direct mRNA degradation or translational inhibition [11]. To date, it has been reported that the miRNA expression profiles differ between in normal tissues and derived tumors, including gastric cancer, and many miRNAs can act as tumor suppressors or oncogenes [12,13,14]. Recently, it was reported that miRNA-134 and miRNA-145 repress SOX2 expression by targeting its coding region in mouse ES cells and the 3'-UTR in human ES cells, respectively [15,16]. However, there have been no reports on miRNA(s) that can regulate SOX2 expression in human gastric cancer.

In the initial step of this study, we performed immunohistochemical analysis of the SOX2 protein in human gastric cancer tissues, in which the DNA methylation statuses of SOX2 had already been examined [10], and found that a certain number of SOX2 expression-negative cases did not show DNA hypermethy-
lulation, leading us to the idea that there is another mechanism underlying SOX2 down-regulation. Accordingly, in this study, we aimed to find miRNAs that target SOX2 expression in human gastric cancers. We found that miRNA-126 (miR-126) repressed SOX2 expression by targeting its 3'-UTR, and then performed functional analyses of miR-126 in gastric cancer cells. To further clarify the importance of miR-126-mediated SOX2 down-regulation in gastric carcinogenesis, we attempted to identify downstream target genes of SOX2 in gastric cancer cells.

Results

The SOX2 3'-UTR is a predicted target of miRNA-126 and -522

In order to find novel miRNAs that regulate SOX2 expression in gastric cancer, we performed computational analysis using a miRNA target database, MicroCosm Targets (formerly miRBase Targets), and tried to identify miRNAs that target the SOX2 3'-UTR according to the following criteria. Considering the position, number, and sequence conservation of miRNA target sites among species, we selected two miRNAs, miR-126 and miR-522, as potential miRNAs targeting the SOX2 3'-UTR (Figure 1). miR-126 has two predictive target sites, which are both near the stop codon of the SOX2 open reading frame (ORF) in the 3'-UTR, whereas the predicted target site of miR-522 is highly conserved in seven species and also located near the SOX2 ORF stop codon in the 3'-UTR (Figure 1).

miR-126 inhibits SOX2 expression in multiple cell lines

To validate the results of computational analysis, we examined whether or not miR-126 and miR-522 can repress the expression level of the endogenous SOX2 protein in SOX2-expression-positive gastric cancer cell lines. As shown in the upper panel of Figure 2A, transfection of the miR-126 mimic molecule (Pre-miR-126) as well as SOX2 siRNA markedly reduced the endogenous SOX2 protein levels in HSC43 cells, but the miR-522 mimic molecule (Pre-miR-522) did not.

To generally evaluate the possibility that miR-126 inhibits SOX2 expression, we transfected Pre-miR-126 and Anti-miR-126 inhibitor (Anti-miR-126) into multiple gastric cancer cell lines. We used the following cell lines for transient transfection experiments: MKN45 (SOX2 positive; miR-126 intermediate) and TGBCl1TKB (SOX2 positive; miR-126 negative) for Pre-miR-126 transfection; and HSC43 (SOX2 positive; miR-126 positive) and NUGC3 (SOX2 very low; miR-126 positive) for Anti-miR-126 transfection (Table 1). Remarkable reductions of the SOX2 protein level were observed in Pre-miR-126-transfected MKN45 and TGBCl1TKB cell lines (Figure 2A). Conversely, Anti-miR-126 transfection up-regulated the SOX2 protein levels in both the HSC43 and NUGC3 cell lines (Figure 2A), indicating that not only exogenous Pre-miR-126 but also endogenous miR-126 can regulate SOX2 protein levels in gastric cancer cells. We also performed quantitative real-time RT-PCR analysis of SOX2 mRNA expression, and found that exogenous miR-126 modestly but significantly suppressed the SOX2 mRNA level in HSC43 cells (Figure 2B).

Because the SOX2 protein is known to be abundantly expressed in ES cells, we examined whether or not miR-126 inhibits SOX2 protein expression in a mouse ES cell line (SOX2 positive; miR-126 negative). Interestingly, exogenous miR-126 transfection dose-dependently decreased the SOX2 protein level in the mouse ES cells (Figure 2A), suggesting that miR-126 represses SOX2 expression in various species and cell lineages.

miR-126 directly targets the SOX2 3'-UTR through two predicted binding sites

To determine whether or not the predicted target sites for the miRNAs in the 3'-UTR of SOX2 mRNA are responsible for the SOX2 down-regulation, we performed luciferase reporter assays with a vector containing the SOX2 3'-UTR downstream of the luciferase reporter gene. As shown in Figure 3A, significant repression of luciferase activities were observed in HEK293T cells co-transfected with the pGL4-SOX2 3'-UTR vector and Pre-miR-126 or siRNA that targets the SOX2 3'-UTR (Figure 1). On the other hand, Pre-miR-522 had no significant effect on the luciferase activity.

Figure 1. Schematic diagrams of predicted target sites of miR-126 and miR-522 in the SOX2 3'-UTR. The predicted binding sites of miR-126 and miR-522 are indicated (arrowheads) in the SOX2 3'-UTR (1119 bp). The first nucleotide after the stop codon of SOX2 is defined as "1", and the start- and end-positions of the complementary sequence between SOX2 and miRNAs are indicated above or beneath the arrowheads. *The horizontal bar below the SOX2 3'-UTR indicates the region targeted by the SOX2 siRNA. Sequence alignments of miR-126 and miR-522 with their corresponding potential target sites in the SOX2 3'-UTR are presented in each rectangle. The conservation status among species of the predicted binding sites is also indicated in each rectangle.

doi:10.1371/journal.pone.0016617.g001
activity of the pGL4-SOX2 3′-UTR vector compared with NC (Figure 3A). These results, combined with those of Western blot analysis, indicate that miR-126 is a more potential candidate miRNA that represses SOX2 expression in gastric cancer than miR-522.

To examine the direct interaction of miR-126 with the potential target sites in the SOX2 3′-UTR, we carried out luciferase reporter assays with the deletion mutant vector as to the putative miR-126 target sites. As shown in Figure 1, miR-126 has two predicted binding sites, A and B, in the 3′-UTR of SOX2 mRNA. We therefore performed luciferase assays with the wild type pGL4-SOX2 3′-UTR vector (Wt), the vectors with each predicted miR-126 target site deleted, A (Del-A), B (Del-B), or both sites, AB (Del-AB). Intriguingly, each single deletion mutant vector exhibited a low inhibitory effect on luciferase activity compared with the Wt vector after Pre-miR-126 co-transfection (Figure 3B). Moreover, the double deletion mutant vector, Del-AB, showed complete reversal of the inhibitory effect of the Pre-miR-126 co-transfection (Figure 3B), indicating that miR-126 directly inhibits SOX2 expression by targeting the two binding sites in the 3′-UTR of SOX2 mRNA independently.

The inverse correlation between miR-126 and SOX2 expression in some cultured and primary gastric cancer cells

To assess the relationship between miR-126 and SOX2 expression in gastric cancers, we initially examined SOX2 mRNA

---

**Table 1. Expression of SOX2 and miR-126 in gastric cancer cell lines.**

| Cell line     | Protein | mRNA | miR-126 |
|---------------|---------|------|---------|
| TGBC11TKB     | +++     | +++  | -       |
| HSC43         | ++      | +++  | +++     |
| MKN45         | ++      | +++  | +       |
| KATOIII       | +       | +++  | -       |
| AGS           | +       | +++  | -       |
| HSC44PE       | ±       | ++   | ±       |
| NUGC3         | ±       | +    | ++      |
| GCIY          | -       | ±    | ++      |
| NUGC4         | -       | -    | ++      |
| HSC58         | -       | -    | +++     |

*aClassification of band intensity: - , completely invisible; ± , faintly visible; + , visible; ++, clearly visible; +++ , strongly visible.

bmiR-126 expression was measured with TaqMan and calculated by the delta-delta Cq method using RNU6B as an internal control. The intensity of miR-126 to RNU6B was defined as follows: <0.05; ±, 0.05~0.09; +, 0.1~0.79; ++, 0.8~2.0; +++ >2.0.

doi:10.1371/journal.pone.0016617.t001
and protein levels by RT-PCR and Western blot analysis, respectively, in 10 gastric cancer cell lines without DNA methylation of SOX2 (Table 1) [10]. Five of the 10 cell lines showed low or undetectable levels of the SOX2 protein, whereas three of them exhibited a low SOX2 mRNA level (Table 1). We subsequently examined miR-126 expression by TaqMan real-time PCR analysis in these 10 gastric cancer cell lines. Four (NUGC3, GCIY, NUGC4 and HSC58) of the 10 cell lines, whose SOX2 mRNA and protein levels were low, exhibited relatively high expression of miR-126, whereas the other cell lines, except for HSC43 cells, exhibited relatively low expression of miR-126 and a high SOX2 mRNA level (Table 1). These data indicate that the miR-126 expression level is mostly opposite to the SOX2 mRNA and protein levels in gastric cancer cell lines.

To further compare the expression pattern of miR-126 with that of SOX2 in primary gastric cancers, we initially examined the expression levels of SOX2 protein in 15 primary gastric cancer tissue samples without DNA methylation of SOX2 by immunohistochemistry. We found that almost all non-cancerous mucosae showed SOX2-positive signal only in the cell nuclei within the neck of the gastric glands (Figure 4A), whereas nine of the 15 cases exhibited low or undetectable levels of the SOX2 protein compared with the paired non-cancerous mucosae (Figure 4).

Next, total RNA was isolated from these 15 gastric cancers and paired non-cancerous tissues, and the miR-126 expression levels were determined by TaqMan real-time PCR analysis. Four of the 15 cases exhibited significantly high levels of miR-126 expression, whereas three of them did low miR-126 levels in comparison with the adjacent non-cancerous mucosae (Figure 4B). Among the miR-126-upregulated cases, three (FG6, FG21 and FG24) exhibited lower levels of SOX2 protein than paired non-cancerous mucosae (Figure 4B), suggesting that high levels of miR-126 expression contribute to low levels of SOX2 protein at least in some primary gastric cancers. There was no significant correlation between the miR-126 expression and sex, age, depth of tumor invasion or histological type (data not shown).

miR-126 enhanced anchorage-dependent and -independent growth of gastric cancer cells

We next evaluated the effect of miR-126 on tumor cell growth. We initially examined the proliferation rates of SOX2-expression positive gastric cancer cell lines, MKN45 and HSC43, after transient transfection of Pre-miR-126. As shown in Figure 5A, the Pre-miR-126-transfected-MKN45 cells formed larger colonies than the NC-transfected-cells. Moreover, the SOX2 siRNA-transfected-MKN45 cells, but not HSC43 cells, significantly increased proliferation compared with the control cells (Figure 5A), suggesting that miR-126-mediated growth stimulation may occur in a SOX2-dependent manner, at least in MKN45 cells.

To determine the role of miR-126 in gastric tumorigenesis, we next carried out soft agar colony formation assays of gastric cancer cell lines after Pre-miR-126 transfection (Figure 5B and C). As shown in Figure 5B, the Pre-miR-126-transfected-MKN45 and HSC43 cells exhibited significant growth advantages compared with the control NC-transfected-cells. Moreover, the SOX2 siRNA-transfected-MKN45 cells, but not HSC43 cells, significantly increased proliferation compared with the control cells (Figure 5A), suggesting that miR-126-mediated growth stimulation may occur in a SOX2-dependent manner, at least in MKN45 cells.

Next, total RNA was isolated from these 15 gastric cancers and paired non-cancerous tissues, and the miR-126 expression levels were determined by TaqMan real-time PCR analysis. Four of the 15 cases exhibited significantly high levels of miR-126 expression, whereas three of them did low miR-126 levels in comparison with the adjacent non-cancerous mucosae (Figure 4B). Among the miR-126-upregulated cases, three (FG6, FG21 and FG24) exhibited lower levels of SOX2 protein than paired non-cancerous mucosae (Figure 4B), suggesting that high levels of miR-126 expression contribute to low levels of SOX2 protein at least in some primary gastric cancers. There was no significant correlation between the miR-126 expression and sex, age, depth of tumor invasion or histological type (data not shown).

miR-126 enhanced anchorage-dependent and -independent growth of gastric cancer cells

We next evaluated the effect of miR-126 on tumor cell growth. We initially examined the proliferation rates of SOX2-expression positive gastric cancer cell lines, MKN45 and HSC43, after transient transfection of Pre-miR-126. As shown in Figure 5A, the Pre-miR-126-transfected-MKN45 and HSC43 cells exhibited significant growth advantages compared with the control NC-transfected-cells. Moreover, the SOX2 siRNA-transfected-MKN45 cells, but not HSC43 cells, significantly increased proliferation compared with the control cells (Figure 5A), suggesting that miR-126-mediated growth stimulation may occur in a SOX2-dependent manner, at least in MKN45 cells.

To determine the role of miR-126 in gastric tumorigenesis, we next carried out soft agar colony formation assays of gastric cancer cell lines after Pre-miR-126 transfection (Figure 5B and C). As shown in Figure 5B, the Pre-miR-126- and SOX2 siRNA-transfected-MKN45 cells formed larger colonies than the NC-transfected cells in soft agar at 9 days after transfection. We then performed soft agar colony formation assays using a CytoSelect 96-Well In Vitro Tumor Sensitivity Assay Kit, which can be used
to count the colony-forming cells by means of a colorimetric method, such as the WST-8 assay, making the assays quick and accurate. Exogenous miR-126 over-expression as well as SOX2 siRNA transfection significantly enhanced the anchorage-independent colony formation of MKN45 and HSC43 cells compared with the control cells at 9 to 10 days after transfection, respectively (Figure 5C). These results suggest that miR-126 may promote the tumorigenicity of gastric cancer cells through suppression of SOX2 expression.

miR-126 controls novel SOX2 target genes in gastric cancer cells

To further understand the potential effects of miR-126-mediated SOX2 down-regulation on the gene expression change in gastric cancer cells, we first attempted to identify candidate downstream target genes of SOX2. We transiently expressed exogenous SOX2 in NUGC3 cells by using an adenovirus system, and changes in expression were determined by cDNA microarray analysis (GEO accession No. GSE23589). Among 41,174 probes, 366 known genes were up-regulated (>2.0-fold) and 369 known genes were down-regulated (<0.5-fold) by SOX2-over-expression in NUGC3 cells compared with control GFP-over-expressing cells (Table S1). Representative microarray results are summarized in Table 2, and we found the significant up-regulation of exogenous SOX2 (20.20-fold), supporting the validity of this experiment. Intriguingly, there were many cancer-related genes that could be novel downstream targets of SOX2 (for example, LTF, PPP2R1B, TGFBR2, SERPINE1, MMP9, HMGA1, SOX9 and PLAC1), and squamous cell differentiation markers KRT6A and KRT6C, whose amino acid sequences are highly conserved among the KRT6 family members and virtually identical to one of the known SOX2 downstream genes, KRT6A (Table 2 and Table S1) [17]. We validated the microarray results by RT-PCR analysis in NUGC3 cells after SOX2 over-expression, and representative results are shown in Figure 6A. Most of these genes also showed changes in their expression after SOX2 over-expression at least in one more gastric cancer cell line among the two to three cell lines we investigated (data not shown).

To determine the target genes of SOX2 controlled by miR-126 in gastric cancer cells, we next performed SOX2 knockdown experiments and further screened for candidate target genes. SOX2 knockdown by Pre-miR-126 and siRNA was confirmed by Western blot analysis in SOX2-expression-positive gastric cancer cell lines MKN45 and HSC43 (Figure 2A), and the subsequent expression changes of the putative SOX2 downstream target genes were preliminarily analyzed by RT-PCR in these cell lines, and then by quantitative real time RT-PCR in HSC43 cells. Among over 20 cancer-related genes we investigated, only two showed changes in expression after SOX2 knockdown (data not shown). First, differentiation marker KRT6A expression, which was up-regulated by SOX2 over-expression, was significantly down-regulated by Pre-miR-126 as well as SOX2 siRNA transfection in HSC43 cells (Figure 6B). Second, placenta- and tumor-specific PLAC1 expression, which was down-regulated by SOX2 over-
expression, was significantly up-regulated by SOX2 knockdown with Pre-miR-126 and siRNA in HSC43 cells (Figure 6B). These results indicate that miR-126 can control KRT6A and PLAC1 expression by down-regulating SOX2 expression in gastric cancer cells, and these genes might be downstream target genes of SOX2 contributing to gastric carcinogenesis.

Discussion

We previously reported that SOX2 expression was frequently down-regulated in human gastric carcinoma tissues (about half of the total cases), some of which was due to aberrant DNA methylation (about 16% of the total cases) [10]. Therefore, the mechanisms underlying loss of SOX2 expression have not yet been defined in more than half of the cases. In this study, we demonstrated that miR-126 decreased the SOX2 mRNA and protein expression levels in gastric cancer cell lines. In addition, we found that miR-126 expression was inversely correlated with SOX2 expression in certain cultured and primary gastric cancer cells without DNA methylation of SOX2, indicating that aberrant miR-126 expression may be a novel mechanism underlying SOX2 down-regulation in gastric cancer. Furthermore, Pre-miR-126 over-expression promoted anchorage-dependent and -independent growth of gastric cancer cell lines and increased oncogenic PLAC1 expression in a gastric cancer cell line. These findings suggest that miR-126 may be an oncogenic miRNA that controls SOX2 expression in gastric cancer cells. Besides gastric cancer, Pre-miR-126 over-expression reduced the SOX2 protein level in mouse ES cells, suggesting that miR-126 may generally control SOX2 expression, at least in two species (human and mouse) and various cell lineages, including ES cells.

MiR-126 is known as an endothelium-specific miRNA, and has been reported to promote angiogenesis by targeting SPRED1 and PIK3R2, which normally inhibit VEGF signaling [18,19,20]. Moreover, it has been reported that miR-126 inhibits apoptosis of acute myeloid leukemia (AML) cells and enhanced the colony-forming ability of mouse bone marrow progenitor cells through targeting Polo-like kinase 2 (PLK2), a tumor suppressor [21]. On the contrary, miR-126 has also been reported to be a tumor suppressive miRNA, inhibiting tumor cell growth through...
Second, miR-126 has two binding sites in the 3′-UTR recognition and repression of the target transcript [25,26]. It is well known that perfect "seed" pairing is required for both target recognition and repression [25,26]. However, miR-522 has only one. It has been reported that when targeting a miRNA has multiple binding sites in the 3′-UTR of its target gene, the binding sites could be simultaneously targeted by the miRNA [27,28]. These findings combined with our present data suggest that the presence of multiple complementary target sites and perfect matches between these ones and miRNA "seed" region are good indicators for finding functional miRNAs.

In this study, miR-126 expression was found to be relatively high in SOX2-expression-negative gastric cancer cell lines, and was aberrantly up-regulated in some primary gastric cancer cases compared with the paired non-cancerous mucosae. However, the mechanism underlying this aberrant miR-126 expression in gastric cancer remains to be elucidated. It was previously reported that the CpG island was aberrantly hypermethylated in some primary gastric cancer cases compared with the paired non-cancerous mucosae. However, the mechanism underlying this aberrant miR-126 expression in gastric cancer remains to be elucidated. It was previously reported that the CpG island but not with amplification or mutation of the genomic locus [21,29]. In fact, we observed that some gastric cancer cell lines exhibited restored miR-126 expression after treatment with a demethylating agent, 5-aza-2′-deoxycytidine (data not shown). These findings indicate that miR-126 expression may be epigenetically regulated in gastric cancer cells.

We performed cDNA microarray analysis to identify the downstream target genes of SOX2 in gastric cancer cells, and found that many tumor-associated genes exhibited significant changes in expression after SOX2-overexpression (e.g., *LTF*, *PPP2R1B*, *TGFB2*, *SERPINE1*, *MMP9*, *HMGA1* and *SOX9*). Furthermore, most of them also exhibited changes in their expression after SOX2-overexpression, at least in two gastric cancer cell lines. These results indicate that SOX2 might regulate the expression of these tumor-associated genes, thereby contrib-

| Gene symbol | Gene name                         | Fold change |
|-------------|-----------------------------------|-------------|
| SPP1        | secreted phosphoprotein 1 (osteopontin) | 63.54       |
| SOX2        | SRY (sex determining region Y)-box 2 | 20.20       |
| IL1R2       | interleukin 1 receptor, type II   | 12.53       |
| KRT6E       | keratin 6C (virtually identical to KRT6A) | 10.52       |
| LTF         | lactotransferrin                   | 7.85        |
| GSN         | gelsolin (amyloidosis, Finnish type) | 5.97        |
| KRT6C       | keratin 6C (virtually identical to KRT6A) | 7.07        |
| PPP2R1B     | protein phosphatase 2 regulatory subunit A beta isoform | 3.86        |
| KLK10       | kallikrein-related peptidase 10    | 3.24        |
| EPB41L1     | erythrocyte membrane protein band 4.1-like 1 | 2.81        |
| PRKAR2B     | protein kinase, cAMP-dependent, regulatory, type II, beta | 2.75        |
| TGFB2       | transforming growth factor, beta receptor II (70/80kDa) | 2.73        |
| SOCS1       | suppressor of cytokine signaling 1  | 2.57        |
| APAF1       | apoptotic peptidase activating factor 1 | 2.22        |
| IL7R        | interleukin 7 receptor             | 0.13        |
| SERPINE1    | serpin peptidase inhibitor, clade E, member 1 (PAI-1) | 0.15        |
| MMP9        | matrix metalloproteinase 9         | 0.27        |
| PLAC1       | placenta-specific 1                | 0.28        |
| PDZK1IP1    | PDZK1 interacting protein 1         | 0.29        |
| SERPINB2    | serpin peptidase inhibitor, clade B, member 2 (PAI-2) | 0.32        |
| HMGAI       | high mobility group AT-hook 1       | 0.37        |
| SERPINB5    | serpin peptidase inhibitor, clade A, member 5 (PAI-3) | 0.38        |
| H19         | H19, imprinted maternally expressed untranslated mRNA | 0.42        |
| SOX9        | SRY (sex determining region Y)-box 9 | 0.47        |

doi:10.1371/journal.pone.0016617.t002

Table 2. Representative results of microarray analysis by SOX2 over-expression.
uting to gastric carcinogenesis. However, we could not observe any significant changes in expression of these genes after SOX2 knockdown by Pre-miR-126 or siRNA, at least in the cell lines we tested. There are some possible reasons for this discrepancy. First, it has been reported that a different expression level of SOX2 switches the regulation of target gene expression from up- to down-regulation, or vice versa [30,31]. In this study, the expression levels of SOX2 were quite different among the cell lines that were used for the over-expression and knockdown experiments. Second, it is well known that stem cell transcription factors, such as SOX2, OCT3/4 and Nanog, cooperatively interact with their target genes’ promoters and control their gene expression, being so-called “transcriptional cofactors”. These expression differences and/or transcriptional cofactors might also be critical for control of expression of the downstream target genes of SOX2 in gastric cancer cells, and further studies are necessary to clarify the roles of SOX2 in the regulation of its target genes.

Expression of KRT6A and PLAC1 was significantly changed by both SOX2 over-expression and knockdown, suggesting that SOX2 is the critical regulatory factor for these two genes in gastric cancer cells. KRT6A is a member of the cytokeratin gene family, and recently it was reported that ectopic SOX2 over-expression up-regulated the KRT6A mRNA level in a lung adenocarcinoma cell line [17]. In the present study, we demonstrated the possibility that KRT6A expression is also positively regulated by SOX2 in gastric cells, but the role of KRT6A in gastric carcinogenesis remains unclear. Thus, further investigations are necessary to elucidate the roles of KRT6A in gastric carcinogenesis.

On the other hand, PLAC1, a recently described X-linked gene exhibiting expression restricted to the placenta, is also expressed in a wide variety of human cancers, including gastric cancer [32,33]. Kosowski et al. reported that siRNA-mediated knockdown of PLAC1 decreased cell motility, migration and invasion, and induced G1-S cell cycle arrest with nearly complete abrogation of proliferation in breast cancer cell lines [34]. In this study, we demonstrated that SOX2 negatively regulates PLAC1 expression in gastric cancer cell lines, and propose a novel hypothesis that miR-126 inhibits SOX2 expression and consequent changes in the expression of some SOX2 target genes, such as PLAC1, thereby contributing to gastric carcinogenesis.

In conclusion, for the first time, we demonstrated that miR-126 is a novel oncogenic miRNA, which targets SOX2, and that downstream pro-oncogenic target genes of SOX2, such as PLAC1, may contribute to gastric carcinogenesis. These findings have important implications for not only explaining the loss of SOX2 expression in gastric cancers, but also for understanding the transcriptional regulatory mechanisms of SOX2 in other various cell lineages, such as ES cells. Taken together, our findings may lead
to new diagnostic and therapeutic approaches for gastric cancer, and provide new insights into the transcriptional regulation of SOX2.

**Materials and Methods**

**Ethics Statement**

Written informed consent was obtained from all subjects, and the study was approved by the Ethics Committee of Tokyo Medical and Dental University.

**Cell lines and tissue samples**

We used 10 human gastric cancer cell lines (HSC43, MKN45, TGBCl1TKB, NUGC3, KATOIII, AGS, HSC44PE, GCIY, NUGC4 and HSC50) and one human embryonic kidney cell line (HEK293T) in this study, as described previously [10,35]. All the cell lines were cultured in appropriate medium. Mouse ES cell line BL6 was obtained from Dr. Hirobumi Teraoka (Tokyo Medical and Dental University Medical Research Institute, Japan), and was cultured as described previously [36]. A total of 16 primary gastric carcinoma tissue samples and corresponding non-cancerous gastric mucosal tissues were obtained, as described previously [10].

**miRNA mimic and inhibitor transfection**

Gastric cancer cells were transfected with Precursor Molecules mimicking miR-126 (Pre-miR-126), miR-522 (Pre-miR-522) (Applied Biosystems, Foster City, CA), SOX2 siRNA (sense, 5'-GAAGGUACCUUGUAAAGAUCG-3'; and anti-sense, 5'-UC-UUACAGGGGUUCCAUUCCCG-3'; Sigma-Aldrich, St. Louis, MO), anti-miR inhibitor miR-126 (Anti-miR-126) (Dharmacon, Lafayette, CO), or scrambled sequence miRNA (Pre-miR Negative Control MO), according to the manufacturer's instructions. The expression levels of miRNA were harvested for Western blot or RT-PCR analyses.

**Western blot**

Western blot analyses were performed as described previously [10]. The primary antibodies used were rabbit anti-SOX2 (1:1000; Cell Signaling Technology, Danvers, MA) and mouse anti-α-tubulin (1:200; Santa Cruz Biotechnology, CA). The secondary antibodies used were alkaline phosphatase-conjugated anti-mouse IgG or anti-rabbit IgG (1:2000; Bio-Rad Laboratories, Hercules, CA). Blots were developed with Immun-Star® AP Substrate (Bio-Rad Laboratories). We used α-tubulin as an internal protein loading control, and the band intensities were defined as described in the footnote of Table 1 when 100 μg of protein was loaded per lane.

**RT-PCR and quantitative real-time RT-PCR**

Total RNA was extracted by using Trizol reagent (Invitrogen, Carlsbad, CA) and then treated with DNA-free™ (Applied Biosystems). RT-PCR and quantitative real-time RT-PCR were performed as described previously [10]. The primer sequences used for all genes are shown in Table S2. For semi-quantitative RT-PCR, GAPDH expression was used as an internal loading control, and the band intensities were defined as described in the footnote of Table 1 under the conditions of 35 PCR cycles.

**Dual luciferase reporter assay**

The 3'-UTR oligonucleotide of SOX2, a 1050 bp fragment containing the last 36 bps of the SOX2 coding region and the putative target sites of miR-126 and miR-522, was amplified by PCR with the following primers: sense, 5'-GGCTCTTAGGCGGCTGACACGCTGCG-3'; and anti-sense, 5'-GGGTCTCAGATCAGATGCCAG-3'. Luciferase constructs were obtained by ligating the wild type 3'-UTR oligonucleotide of SOX2 (W) or nucleotides with the miR-126 target sites deleted (Del-A, -B or -AB) into the XhoI site of the pGLA.13 (luc2/SV40) *firefly* luciferase reporter vector (Promega, Madison, WI). HEK293T cells were co-transfected with HiPerFect (Qiagen, Hilden, Germany) with 10 ng of the pGLA.13 vector containing or not containing the 3'-UTR sequence (for normalization of the non-specific effects on pGLA.13-3'-UTR vector of miRNAs), 4 ng of the pGLA.74 (lBlu/TK) *renilla* luciferase control vector (for normalization of the transfection efficiency), and 30 nM Pre-miR-126, Pre-miR-522, SOX2 siRNA, or Pre-miR-NC. Luciferase activity was measured 24 h after transfection using a Dual-Luciferase Reporter Assay System (Promega). Relative luciferase activity was calculated by normalizing the *firefly* luminescence as to the *renilla* luminescence.

**Immunohistochemistry**

Paraffin-embedded tissue samples were sectioned, deparaffinized, and then pretreated by autoclaving in 10 mM citric acid buffer for 15 min to remove antigenicity. After the peroxidase activity had been blocked with 3% H2O2-methanol for 15 min, the sections were incubated with 10% normal goat serum in PBS to block nonspecific protein binding, followed by incubation with primary antibody against SOX2 (1:300; Millipore) at 4°C overnight. Then, the sections were incubated with horseradish peroxidase-labeled goat anti-mouse-rabbit antibody (Dako, Carpenteria, CA) for 30 min at room temperature, and the signal was amplified and visualized with diaminobenzidine-chromogen, followed by counterstaining with hematoxylin. Expression was considered to be “positive” when 10% or more cancer cells were stained.

**Quantitative real-time RT-PCR of miRNA**

Total RNA was extracted by using Trizol reagent (Invitrogen) and then treated with DNA-free™ (Applied Biosystems) for cell lines. On the other hand, paraffin-embedded tissue samples were sectioned into 10 μm-thick, deparaffinized under RNase-free condition, and then total RNA was extracted by using RecoverAll™ Total Nucleic Acid Isolation Kit (Applied Biosystems, Foster City, CA) according to manufacturer’s instructions. Quantitative real-time RT-PCR of miRNA was carried out using a TaqMan Reverse Transcription Kit (Applied Biosystems), TaqMan MicroRNA Assays (Applied Biosystems), and a LightCycler TaqMan Master (Roche Diagnostics, Mannheim, Germany), according to the manufacturer’s instructions. The expression levels of miRNA were calculated by the delta-delta Ct method using RNU6B as an internal control.

**Cell proliferation and soft agar colony formation assays**

We transfected Pre-miR-126, SOX2 siRNA and Pre-miR-NC into HSC43 and MKN45 cell lines to give a final concentration of 50 nM by using MicroPortor MP-100 (Digital BioTechnology, Seoul, Korea), according to the manufacturer’s instructions. The expression levels of miRNA were calculated by the delta-delta Ct method using RNU6B as an internal control.
Briefly, the transfected cells, as described above, were trypsinized, counted and plated in quadruplicate on 96-well plates with Agar Matrix Layer (2×10^4 cells for HSC-43, 1×10^4 cells for MKN45 per well). After incubating the cells for 7 to 8 days at 37 °C and 5% CO2, the soft agar in each well was solubilized, and viable cells, that is, colony-forming cells, were measured with Cell Counting Kit-8 (Dojindo).

Microarray analysis

Adenovirus (Ad)-SOX2 and control Ad-GFP vectors were generated as described previously [10], and used to infect NUGC3 cells at the optimum MOI (infectious units/cell) of 20. At 72 h after infection, total RNA was extracted by using Trizol reagent (Invitrogen) and then treated with DNA-free™ (Applied Biosystems). cDNA microarray analysis was conducted by DNA Chip Research Inc. (Kanagawa, Japan) with Whole Human Genome Oligo DNA Arrays (Agilent Technologies, Santa Clara, CA). The microarray data is Minimum Information About a Microarray Experiment (MIAME) compliant and has been deposited in a MIAME compliant database, Gene Expression Omnibus (GEO). The GEO accession number is GSE23589.

References

1. Wegner M (1999) From head to toe: the multiple facets of Sox proteins. Nucleic Acids Res 27: 1409-1410.
2. Kamachi Y, Uchikawa M, Kondoh H (2000) Pairing SOX off with partners in the regulation of the embryonic development. Trends Genet 16: 182-187.
3. Wilson M, Koopman P (2002) Matching SOX: partner proteins and co-factors of the SOX family of transcriptional regulators. Cur Upin Genet Dev 12: 441-446.
4. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, et al. (2005) Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122: 947-956.
5. Masui S, Nakatake Y, Toyosaka Y, Shimosato D, Yagi R, et al. (2007) Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol 9: 625-635.
6. Yuan H, Zebeli N, Baulico C, Dailey L (1995) Developmental-specific activity of the FGF-4 enhancer requires the synergistic action of Sox2 and Oct-3. Genes Dev 9: 2635-2645.
7. Ishii Y, Rex M, Scotting JJ, Yassagi S (1998) Region-specific expression of chicken Sox2 in the developing gut and lung epithelium: regulation by epithelial-mesenchymal interactions. Dev Dyn 215: 464-471.
8. Okah T, Pevny LH, Hogan BL (2006) Sox2 is required for development of taste bud sensory cells. Genes Dev 20: 2654-2659.
9. Li X, Eishi Y, Bai YQ, Sakai H, Akiyama Y, et al. (2004) Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma. Int J Oncol 24: 257-263.
10. Otusbo T, Akiyama Y, Yanagihara K, Yuasa Y (2007) SOX2 is frequently amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41: 1238–1242.
11. Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, et al. (2008) E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis. Br J Cancer 98: 824–831.
12. Esquela-Kerscher A, Slack FJ (2006) Oncomirs - microRNAs with a role in oncogenesis. Curr Opin Genet Dev 16: 424–429.
13. Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos I (2008) MicroRNA-mediated integration of haemodynamics and Vegf signalling during angiogenesis. Nature 464: 1196-1200.
14. Li Z, Lu J, Sun M, Mi S, Zhang H, et al. (2008) Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A 105: 15355-15360.
15. Guo C, Sah JF, Beard I, Willson JK, Markowitz SD, et al. (2008) The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phospholipidinositol 3-kine signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer 47: 939-946.
16. Zhang J, Du YY, Lin YE, Chen YT, Yang L, et al. (2008) The cell growth suppressor, miR-126, targets IRS-1. Biochem Biophys Res Commun 377: 136–140.
17. Garraway LA, Sellers WR (2006) Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer 6: 215–233.
18. Levin BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB (2003) Prediction of mammalian microRNA targets. Cell 115: 787–798.
19. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
20. Mayr G, Hemann MT, Bartel DP (2007) Disrupting the pairing between let-7 and Hng2a enhances oncogenic transformation. Science 313: 1576-1579.
21. Xiao C, Calado DP, Galler G, Thai TH, Patterson HC, et al. (2007) Mir-150 controls B cell differentiation by targeting the transcription factor c-Myc. Cell 131: 146–159.
22. Cammarata G, Augugharo L, Salemi D, Agueli C, La Rosa M, et al. (2010) Differential expression of specific microRNA and their targets in acute myeloid leukemia. Am J Hematol 85: 331–337.
23. Boer R, Kopp J, Mallanna S, Desler M, Chakravarthi H, et al. (2007) Elevating the levels of Sox2 in embryonal carcinoma cells and embryonic stem cells inhibits the expression of Sox2:Oct3/4 target genes. Nucleic Acids Res 35: 1773–1786.
24. Kopp J, Ormubere BD, Desler M, Rizzino A (2008) Small increases in the level of Sox2 trigger the differentiation of mouse embryonic stem cells. Stem Cells 26: 903–911.
25. Chen J, Pang XW, Lin FF, Dong XY, Wang HC, et al. (2006) [PLAC1/CP1 gene expression and autologous humoral immunity in gastric cancer patients]. Beijing Da Xue Xue Bao 38: 124–127.
26. Fant M, Farina A, Nagraja R, Schlessinger D (2010) PLAC1 (Placenta-specific 1): a novel, X-linked gene with roles in reproductive and cancer biology. Prenat Diagn 30: 497–502.
27. Kodolowski M, Sahin U, Minnacht-Kraus R, Seitz G, Huber C, et al. (2007) A placenta-specific gene ectopically activated in many human cancers is essentially involved in malignant cell processes. Cancer Res 67: 9528–9534.
28. Fazil Z, Akiyama Y, Fukamachi H, Yanagihara K, Yuasa Y (2007) Transcription factor SOX2 up-regulates stomach-specific pepinoigen A gene expression. J Cancer Res Clin Oncol 133: 263-269.
29. Fujimoto H, Aashiha K, Shinzui-Saito K, Berda R, Tanaka Y, et al. (2008) Vascular endothelial growth factor promotes proliferation and function of hepatocyte-like cells in embryoid bodies formed from mouse embryonic stem cells. J Hepatol 48: 962–973.